Advertisement

Internal Medicine

Home Internal Medicine
Most patients with immunoglobulin G subclass 4-related disease have increased levels of immunoglobulin E

Increases in IgE, Eosinophils, Mast Cells Can ID IgG4-RD

Levels of IgE at diagnosis may be able to identify patients with IgG4-related disease, disease relapse
Community antibacterial consumption comprises about 85 to 95 percent of total antibacterial consumption

Community Consumption Comprises Most Antibacterial Use

Higher proportion of community consumption in countries with high levels of total consumption
End-tidal carbon dioxide levels are prognostic for patients with chronic thromboembolic pulmonary hypertension

Tidal CO2 Prognostic for Chronic Thromboembolic Pulmonary HTN

ETCO2 dichotomized at 29 mm Hg significantly associated with reduced overall survival
Canakinumab at a dose of 150 mg every three months is associated with reduced rate of cardiovascular events among patients with previous myocardial infarction

Canakinumab 150 mg Tied to Reduced Rate of Cardiac Events

150-mg dose met prespecified threshold for significance for primary and secondary end points
Rivaroxaban plus aspirin is superior to aspirin alone for patients with stable atherosclerotic vascular disease

Rivaroxaban Plus Aspirin Superior for Stable Atherosclerotic Disease

Primary outcome for fewer patients receiving rivaroxaban plus aspirin, but more major bleeding
Use of androgen-deprivation therapy may increase the risk of certain cardiovascular conditions in men with prostate cancer

Androgen-Deprivation Therapy May Carry Cardiovascular Risks

Findings in men with clinically localized prostate cancer initially under active surveillance
Many patients at risk for atrial fibrillation probably do have the condition but have not been diagnosed

Incidence of Undiagnosed A-Fib May Be Substantial

In new study using insertable cardiac monitors, rate of AF detection was 40 percent at 30 months
Bivalirudin is not associated with a lower rate of the composite of any cause death

No Reduction in Composite End Point for Bivalirudin in PCI

Patients receiving bivalirudin vs heparin saw no reduction in composite of death, MI, major bleeding
For patients with atrial fibrillation who undergo percutaneous coronary intervention

Dual Therapy Noninferior to Triple Therapy for A-Fib With PCI

And lower risk of bleeding with dabigatran and P2Y12 inhibitor dual therapy versus triple therapy
At its current price

More Evidence Evolocumab Exceeds Cost-Effectiveness

Findings for addition of evolocumab to standard tx in atherosclerotic cardiovascular disease